Cancer multidrug resistance: A review of recent drug discovery research

IDrugs

Volumn 5, Issue 4, 2002, Pages 349-355

  Liscovitch, Mordechai ^a   Lavie, Yaakov ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Steralx Pharmaceuticals Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANNAMYCIN; ANTINEOPLASTIC AGENT; BIRICODAR; CARRIER PROTEIN; CYCLOSPORIN A; DEXNIGULDIPINE; DOXORUBICIN; ELACRIDAR; ERYTHROMYCIN; FLUPHENAZINE; GLYCOPROTEIN P; LANIQUIDAR; MITOTANE; MULTIDRUG RESISTANCE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE; OC 144 093; PROGESTERONE; PROTEIN INHIBITOR; QUININE; RESERPINE; RITUXIMAB; TAMOXIFEN; TARIQUIDAR; THALIDOMIDE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; XR 9567; ZOSUQUIDAR;

AREA UNDER THE CURVE; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; HUMAN; MOLECULE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; SIDE EFFECT; TUMOR CELL;

EID: 0013237486     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res (1993) 53(4):747-754. An excellent entry point into the MDR field, focusing on earlier studies of P-gp, its discovery, cloning and inhibition.
2. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev (1990) 42(3):155-199.
3. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V: Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature (1985) 316(6031):817-819.
4. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res (2001) 42(7):1007-1017.
5. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 92(16):1295-1302. A comprehensive overview of MDR proteins belonging to the MRP family.
6. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA (1998) 95(26):15665-15670.
7. Borst P, Schinkel AH: What have we learn thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer (1996) 32A(6):985-990.
8. Johnstone RW, Ruefli AA, Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci (2000) 25(1):1-6. A healthy dose of P-gp physiology in a field dominated by oncology. Covers all the roles of P-gp in normal tissues.
9. Loo TW, Clarke DM: Molecular dissection of the human multidrug resistance P-glycoprotein. Biochem Cell Biol (1999) 77(1):11-23.
10. El-Deiry WS: Role of oncogenesis in resistance and killing by cancer therapeutic agents. Curr Opin Oncol (1997) 9(1):79-87.
11. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance of P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res (1981) 41(5):1967-1972. Opening the floodgates, this paper showed that verapamil could inhibit MDR, indicating that off-the-shelf biochemicals could be utilized to inhibit P-gp.
12. Ferry DR, Traunecker H, Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer (1996) 32A(6):1070-1081.
13. Holt V, Kouba M, Dietel M, Vogt G: Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol (1992) 43(12):2601-2608.
14. Hegewisch-Becker S: MDR1 reversal: Criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia (1996) 10(Suppl 3):S32-S38.
15. Van Zuylen L, Nooten K, Sparreboom A, Verweij J: Development of multidrug-resistance convertors: Sense or nonsense? Invest New Drugs (2000) 18(3):205-220. An outstanding review of recent results from clinical studies of candidate MDR drugs, providing a thorough and lucid presentation of the problems involved in translation of in vitro studies on MDR into clinical reality.
16. Sonneveld P, Wiemer E: Inhibitors of multidrug resistance. Curr Opin Oncol (1997) 9(6):543-548.
17. National Institutes of Health: Intensive compared with nonintensive chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome. April 17 (2002) Internet Site http://clinicaltrials.gov.
18. National Institutes of Health: Combination chemotherapy plus PSC 833 followed by interleukin-2 in treating older patients with acute myeloid leukemia. April 17 (2002) Internet Site http://clinicaltrials.gov.
19. National Institutes of Health: Combination chemotherapy with or without PSC 833, peripheral stem cell transplantation, and/or interleukin-2 in treating patients with acute myeloid leukemia. April 17 (2002) Internet Site http://clinicaltrials.gov.
20. National Insitutes of Health: Combination chemotherapy with or without PSC 833 in treating patients with relapsed or refractory multiple myeloma. April 17 (2002) Internet Site http://clinicaltrials.gov.
21. Schering AG: Drug development update - MS-209. Company Communication (2001) June 28.
22. Xenova Group plc: Xenova Group plc preliminary results for the year ended 31 December 2001. Press Release (2002) February 19.
23. National Institutes of Health: P-glycoprotein antagonist, tariquidar, in combination with doxorubicin (adriamycin), vinorelbine (navelbine), or docetaxel to treat children with solid tumors. April 17 (2002) Internet site http://clinicaltrials.gov.
24. Vertex Pharmaceuticals Inc: Pipeline and products. January 08 (2002) Company World Wide Web Site http://www.vpharm.com.
25. National Institutes of Health: R101933 combined with chemotherapy in treating patients with metastatic breast cancer that has not responded to previous chemotherapy. April 17 (2002) Internet Site http://clinicaltrials.gov.
26. National Insititutes of Health: A study of combination chemotherapy and surgical resection in the treatment of adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine and etoposide with daily mitotane before and after surgical resection. April 17 (2002) Internet Site http://clinicaltrials.gov.
27. Ontogen Corp: Ontogen appoints Steven S Cowell to Board of Directors. Press Release (2002) February 13.
28. Eli Lilly & Co: Lilly outlines its strategy to become the pharmaceutical growth company of the decade. Press Release (2001) October 24
29. Planting AST, Van Der Gaast A, Sparreboom A et al.: Phase I and pharmacokinetic study targeting a 100 ng/ml plasma concentration of the potent multidrug resistance modulator GF-120918 with doxorubicin in patients with advanced solid tumors. Proc Am Soc Clin Oncol (1998) 17:Abs 765.
30. Andreeff M, Giles F, Kornblau S, Konopleva M, Leysath C, Jackson C, Edwards K, Ross B, Faldas MG, Williams AH, Estey E, Kantarjian H: Phase I study of annamycin, a novel liposomal anthracycline, in patients with relapsed/refractory acute myleoid lymphoid leukemias. Proc Am Soc Clin Oncol (2001) 20:Abs 1211.
31. Bouffard DY, Ohkawa T, Kijima H, Irie A, Suzuki T, Curcio LD, Holm PS, Sassani A, Scanlon KJ: Oligonucleotide modulation of multidrug resistance. Eur J Cancer (1996) 32A(6):1010-1018.
32. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC: Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem (1996) 271(32):19530-19536.
33. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC: Glucosylceramide: A marker for multiple-drug resistant cancers. Anticancer Res (1998) 18(1B):475-480.
34. Lucci A, Giuliano AE, Han TY, Dinur T, Liu YY, Senchenkov A, Cabot MC: Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int J Oncol (1999) 15(3):535-540.
35. Liu YY, Han TY, Giuliano AE, Cabot MC: Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem (1999) 274(2):1140-1146.
36. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC: Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem (2000) 275(10):7138-7143.
37. Senchenkov A, Litvak DA, Cabot MC: Targeting ceramide metabolism - A strategy for overcoming drug resistance. J Natl Cancer Inst (2001) 93(5):347-357. A review on the role of ceramide and glucosylceramide in apoptosis, its involvement in mediating MDR and the possible implications for MDR therapy.
38. Pierre A, Leonce S, Perez V, Atassi G: Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: Kinetics of uptake and efflux in sensitive and resistant cell lines. Cancer Chemother Pharmacol (1998) 42(6):454-460.
39. Folkman J: Clinical applications of research on angiogenesis. New Engl J Med (1995) 333(26):1757-1763.
40. Folkman J: Angiogenesis-dependent diseases. Semin Oncol (2001) 28(6):536-542. Problems and prospects in the application of anti-angiogenic therapy in oncology, with an emphasis on recent advances in the utilization of thalidomine in multiple myeloma.
41. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide4 in refractory multiple myeloma. New Engl J Med (1999) 341(21):1565-1571.
42. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I: Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug. Br J Haematol (2000) 108(2):391-393.
43. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 96(9):2943-2950.
44. Shtil AA, Turner JG, Dalton WS, Yu H: Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: Role of cytotoxic T-lymphocytes. Leuk Lymphoma (2000) 38(1-2):59-70.
45. Wilson WH: Chemotherapy sensitization by rituximab: Experimental and clinical evidence. Semin Oncol (2000) 27(6 Suppl 12):30-36.
46. Isis Pharmaceuticals Inc (Dean NM, Manoharan M): Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression. US-06001991 (1999).
47. Hybridon Inc (Symth AP): Oligonucleotides with anti-MDR1 gene activity. US-05866699 (1999).
48. Board of Trustees of University of Illinois (Shtil AA, Robinson IB): Methods for preventing multidrug resistance in cancer cells. US-06171786 (2001).
49. Synold TW, Dussault I, Forman BM: Methods of modulating drug clearance mechanisms by altering SXR activity. US-2002022599 (2002).
50. Shayman JA, Radin NS: Amino ceramide-like compounds and therapeutic methods of use. US-2001041735 (2001).
51. US Department of Health and Human Services (Gottesman MM, Pastan I, Ueda K): Methods of inducing multidrug resistance using human MDR1 cDNA. US-05928637 (1999).
52. Yeda R & D Co (Liscovitch M, Lavie Y): Use of steroidal alkaloids to reverse multidrug resistance. WO-00149279 (2001).
53. PharmaMar SA (Fernandez Puentes JL, Garcia Gravalos D, Rodriguez Quasada A): Methods of treatment using lamellarin-class alkaloids. US-06087370 (2000).